Sarissa Capital Management issued the following statement regarding Amarin: "Amarin shareholders have sent a loud and clear message repudiating the incumbent Amarin board. Sarissa thanks fellow shareholders for their support in a resounding victory against the Amarin board. Our estimate is that up to nearly 80% of shareholder votes were in support of Sarissa. As Amarin’s largest shareholder, we are grateful for the opportunity to remake Amarin for the benefit of all shareholders. Vascepa, the foundation on which Amarin is built, is a tremendous drug that is compelling for patients and payors – a unique proposition for a drug. While there is a lot of work to be done, we remain confident in our ability to leverage Vascepa’s rare and highly beneficial profile to unlock tremendous value for all shareholders."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMRN:
- Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
- Amarin, CSL Seqirus enter exclusive license, distribution agreement for VAZKEPA
- Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
- Amarin Sets the Record Straight on Sarissa’s Latest Misstatements